On this page
Periogard Alcohol Free
Chlorhexidine Gluconate · Rinse
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Chlorhexidine Gluconate | 1.2 mg/mL | 1667684 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Decreased Cell Wall Integrity [PE] | PE | All 26 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 203212-001 | PERIOGARD | SOLUTION | CHLORHEXIDINE GLUCONATE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 1 | Manufacturing (CMC) | Approved | October 12, 2018 | Unknown |
| Original application | 1 | Approved | January 28, 2016 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260213). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. PerioGard® has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS .
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) therapy should be initiated directly following a dental prophylaxis. Patients using PerioGard® should be reevaluated and given a thorough prophylaxis at intervals no longer than six months. Recommended use is twice daily oral rinsing for 30 seconds, morning and evening after toothbrushing. Usual dosage is 1/2 fl. oz. ("15 mL" line in dosage cap) of undiluted PerioGard®. Patients should be instructed not to rinse with water or other mouthwashes, brush teeth, or eat immediately after using PerioGard®. PerioGard® is not intended for ingestion and should be expectorated after rinsing.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS PerioGard® should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.
Warnings
openFDA Drug LabelingWARNINGS The effect of PerioGard® on periodontitis has not been determined. An increase in supragingival calculus was noted in clinical testing with users of chlorhexidine gluconate oral rinse USP, 0.12% compared with control users. It is not known if chlorhexidine gluconate use results in an increase of subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine. SEE CONTRAINDICATIONS .
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The most common side effects associated with chlorhexidine gluconate oral rinse USP, 0.12% are: (1) an increase in staining of teeth and other oral surfaces, (2) an increase in calculus formation, and (3) an alteration in taste perception; see WARNINGS and PRECAUTIONS . Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with use of chlorhexidine gluconate rinse. The following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1.0%. Among postmarketing reports, the most frequently reported oral mucosal symptoms associated with chlorhexidine gluconate oral rinse USP, 0.12% are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia. Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using chlorhexidine gluconate oral rinse. There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using chlorhexidine gluconate oral rinse.
Description
openFDA Drug LabelingDESCRIPTION PerioGard® (Chlorhexidine Gluconate Oral rinse USP, 0.12%) is an oral rinse containing 0.12% chlorhexidine gluconate (1,1'-hexamethylene bis [5-(p-chlorophenyl) biguanide] di-D-gluconate) in a base containing water, propylene glycol, glycerin, sorbitol, polyoxyl 40 hydrogenated castor oil, flavor, cetylpyridinium chloride, and FD&C blue no. 1. PerioGard® product is a near neutral solution (pH range 5-7). Chlorhexidine gluconate is a salt of chlorhexidine and gluconic acid. Its chemical structure is: Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Ingestion of 1 or 2 ounces of PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) by a small child (~10 kg body weight) might result in gastric distress, including nausea. Medical attention should be sought if more than 4 ounces of PerioGard® Oral Rinse is ingested by a small child.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED PerioGard® is supplied as a blue liquid in 3 different UD presentations 5 ML UD CUP............................... NDC 17856-0272-03 10 ML UD CUP............................. NDC 17856-0272-01 15 ML UD CUP............................. NDC 17856-0272-02 Store at 20° to 25°C (68° to 77°F) excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Rx Only. Keep out of reach of children.
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CHLORHEXIDINE GLUCONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 17856-0272-1 | 17856-0272 | ATLANTIC BIOLOGICALS CORP. | 72 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (17856-0272-1) / 10 mL in 1 CUP, UNIT-DOSE (17856-0272-5) | May 7, 2024 |
| 17856-0272-2 | 17856-0272 | ATLANTIC BIOLOGICALS CORP. | 72 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (17856-0272-2) / 15 mL in 1 CUP, UNIT-DOSE (17856-0272-4) | May 7, 2024 |
| 17856-0272-3 | 17856-0272 | ATLANTIC BIOLOGICALS CORP. | 72 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (17856-0272-3) / 5 mL in 1 CUP, UNIT-DOSE (17856-0272-6) | May 7, 2024 |
| 0126-0272-16 | 0126-0272 | Colgate Oral Pharmaceuticals, Inc. | 473 mL in 1 BOTTLE, PLASTIC (0126-0272-16) | November 18, 2020 |
| 0126-0282-16 | 0126-0282 | Colgate Oral Pharmaceuticals, Inc. | 473 mL in 1 BOTTLE, PLASTIC (0126-0282-16) | October 4, 2021 |
| 17856-0272 | 17856-0272 | ATLANTIC BIOLOGICALS CORP. | — | November 18, 2020 |
| 0126-0272 | 0126-0272 | Colgate Oral Pharmaceuticals, Inc. | — | November 18, 2020 |
| 0126-0282 | 0126-0282 | Colgate Oral Pharmaceuticals, Inc. | — | October 4, 2021 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.